



DOCKET NO.: 21.US18.CIP

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: **Ruoping Chen et al.**

Confirmation No.: **1454**

Serial No.: **09/995,225**

Art Unit No.: **1646**

Filing Date: **November 26, 2001**

Examiner: **Nirmal Singh Basi**

For: **ENDOGENOUS AND NON-ENDOGENOUS VERSIONS OF HUMAN G
PROTEIN-COUPLED RECEPTORS**

Customer No.: **35133**

EXPRESS MAIL INFORMATION

Express Mail Label No: EV146 601 375US

Date Of Deposit: May 10, 2005

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB0/8A, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

This Supplemental Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.

- ☐ before the mailing date of a first Office Action on the merits.
- ☒ after the mailing date of a first Office Action on the merits or after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
- ☐ the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);
- or
- ☒ the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
- ☐ No fee is owed by the applicant(s).
- ☐ In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- ☐ after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see "Statement," and "Fees" below).
- ☒ Copies of the references listed on the attached PTO Form SB/08a, formerly known as PTO Form 1449 is enclosed.

EXCEPT THAT:

- ☐ In view of the voluminous nature of reference @@, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Pursuant to Fed. Reg. Vol. 69, No. 182, dated September 21, 2004, copies of U.S. Patents and U.S. Patent Publications need not be submitted as part of an Information Disclosure Statement.

Statement under 37 C.F.R. § 1.97(e)

- ☐ The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

Statement under 37 C.F.R. § 1.704(d)

- ☐ The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and the communication was not received by any individual designated in § 1.56(c) more than 30 days prior to the filing of the Information Disclosure Statement.

Fees

- ☐ No Fee is owed by the applicant(s).
- ☒ The Supplemental Information Disclosure Statement Fee of **\$180.00** under 37 C.F.R. § 1.17(p) is authorized to be charged to Deposit Account No. 50-1275.

Method of Payment of Fees

- ☐ Attached is a check in the amount of \$_____. This form is submitted in duplicate.
- ☒ Charge Deposit Account No. 50-1275 in the amount of **\$180.00**. This form is submitted in duplicate.
- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
- ☐ No fee or Statement is required under 37 C.F.R. § 1.97(b).


Respectfully submitted,



Michael A. Patané
Registration No. 42,982

Dated: May 10, 2005

COZEN O'CONNOR, P.C.
1900 Market Street, 5th Floor
Philadelphia, PA 19103-3508
(215) 665-6966 – Telephone
(215) 701-2080 - Facsimile



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/995,225
Filing Date	November 26, 2001
First Named Inventor	Ruoping Chen et al.
Art Unit	1646
Examiner Name	Nirmal Singh Basi
Attorney Docket Number	21.US18.CIP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CO	ELBLE, RODGER, J., "Animal Models of Action Tremor," <i>Movement Disorders</i> , 13(3):35-39, (1998)	
	CP	JELJELI, M., ET AL., "Effects of centrolateral or medial thalamic lesions on motor coordination and spatial orientation in rats," <i>Neuroscience Research</i> , 38:155-164, (2000)	
	CQ	KARPE, F. and FRAYN, K.N., "The nicotinic acid receptor--a new mechanism for an old drug," <i>The Lancet</i> , 363:1892-1894, (June, 2004)	
	CR	McNAMARA, J.O. "Drugs Effective in the Therapy of the Epilepsies," <i>Goodman & Gilman's The Pharmacological Basis of Therapeutics</i> , Ninth Edition, Chapter 20, pp. 461-486	
	CS	PORTAS, C.M., ET AL., "A Specific Role for the Thalamus in Mediating the Interaction of Attention and Arousal in Humans," <i>The Journal of Neuroscience</i> , 18(21):8979-8989, (November, 1998)	
	CT	PROBST, WILLIAM C., ET AL., "Sequence Aligment of the G-Protein Coupled Receptor Superfamily," <i>DNA and Cell Biology</i> , 11(1):1-20, (1992)	
	CU	SONNHAMMER, ERIK L.L., ET AL., "A Hidden Markov Model for Predicting Transmembrane Helices in Protein Sequences," <i>Proc. Int. Conf. Intell. Syst. Mol. Biol.</i> , 6:175-82, (1998)	
	CV	ZADINA, J.E., ET AL., "Endomorphins: Novel Endogenous μ -Opiate Receptor Agonists in Regions of High μ -Opiate Receptor Density," <i>Annals New York Academy of Sciences</i> , 897:136-144, (1999)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**A COPY OF THIS REFERENCE WILL NOT BE FORWARDED TO THE U.S. PATENT AND TRADEMARK OFFICE SINCE IT IS BELIEVED TO BE TOO VOLUMINOUS AND EASILY OBTAINABLE BY THE EXAMINER.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.